How to recognize distinctions between pediatric and adult arthritis
Search results for: juvenile idiopathic arthritis
EULAR: Identify Arthritis Early, Treat it Effectively
Recent studies are uncovering genetic and environmental factors at play in the earliest stages of rheumatoid arthritis and medications that are effective in treating juvenile idiopathic arthritis
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
The Classification Challenge of Pediatric Spondylarthritis
Condition often confused with other disorders
Changing Our Thinking on Osteoarthritis
It’s time we changed our thinking on osteoarthritis
Pediatric Clinical Year in Review: 2023
SAN DIEGO—Too many excellent pediatric rheumatology studies to squeeze into one talk? What a good problem to have. Dr. Ardoin first highlighted baricitinib in juvenile idiopathic arthritis.
Growing Up
SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
Changing Treatment Patterns for Patients with JIA
A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.
European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
A Possible Diagnostic Tool: RheumMadness 2022 AI: JIA Subtypes Scouting Report
Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 34
- Next Page »